XML 43 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaboration and Licensing Revenue (Tables)
 9 Months Ended
Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summarized Collaboration and Licensing Revenues
The following tables summarize the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the three and nine months ended September 30, 2017 and 2016.
 
Three Months Ended September 30, 2017
 
Revenue Recognized From
 
Total
 
Upfront and Milestone Payments
 
Research and Development Services
 
ZIOPHARM Oncology, Inc.
$
4,843

 
$
5,530

 
$
10,373

Oragenics, Inc.
262

 
213

 
475

Fibrocell Science, Inc.
604

 
1,079

 
1,683

Genopaver, LLC
68

 
1,354

 
1,422

S & I Ophthalmic, LLC
—

 
376

 
376

OvaXon, LLC
—

 
262

 
262

Intrexon Energy Partners, LLC
625

 
1,278

 
1,903

Persea Bio, LLC
125

 
141

 
266

Ares Trading S.A.
1,597

 
759

 
2,356

Intrexon Energy Partners II, LLC
500

 
316

 
816

Intrexon T1D Partners, LLC
287

 
1,175

 
1,462

Harvest start-up entities (1)
616

 
3,404

 
4,020

Other
979

 
1,762

 
2,741

Total
$
10,506

 
$
17,649

 
$
28,155

(1)
For the three months ended September 30, 2017, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.
 
Three Months Ended September 30, 2016
 
Revenue Recognized From
 
Total
 
Upfront and Milestone Payments
 
Research and Development Services
 
ZIOPHARM Oncology, Inc.
$
4,843

 
$
5,586

 
$
10,429

Oragenics, Inc.
262

 
294

 
556

Fibrocell Science, Inc.
604

 
563

 
1,167

Genopaver, LLC
68

 
1,625

 
1,693

S & I Ophthalmic, LLC
—

 
2,782

 
2,782

OvaXon, LLC
—

 
709

 
709

Intrexon Energy Partners, LLC
625

 
4,230

 
4,855

Persea Bio, LLC
125

 
208

 
333

Ares Trading S.A.
1,597

 
719

 
2,316

Intrexon Energy Partners II, LLC
500

 
372

 
872

Intrexon T1D Partners, LLC
276

 
511

 
787

Harvest start-up entities (1)
425

 
868

 
1,293

Other
895

 
1,903

 
2,798

Total
$
10,220

 
$
20,370

 
$
30,590

(1)
For the three months ended September 30, 2016, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; and AD Skincare, Inc.
 
Nine Months Ended September 30, 2017
 
Revenue Recognized From
 
Total
 
Upfront and Milestone Payments
 
Research and Development Services
 
ZIOPHARM Oncology, Inc.
$
14,527

 
$
16,795

 
$
31,322

Oragenics, Inc.
786

 
733

 
1,519

Fibrocell Science, Inc.
1,814

 
3,561

 
5,375

Genopaver, LLC
205

 
4,410

 
4,615

S & I Ophthalmic, LLC
—

 
751

 
751

OvaXon, LLC
—

 
1,966

 
1,966

Intrexon Energy Partners, LLC
1,875

 
7,034

 
8,909

Persea Bio, LLC
375

 
446

 
821

Ares Trading S.A.
4,791

 
3,683

 
8,474

Intrexon Energy Partners II, LLC
1,500

 
1,421

 
2,921

Intrexon T1D Partners, LLC
823

 
3,059

 
3,882

Harvest start-up entities (1)
1,823

 
10,012

 
11,835

Other
3,735

 
3,259

 
6,994

Total
$
32,254

 
$
57,130

 
$
89,384

(1)
For the nine months ended September 30, 2017, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.
 
Nine Months Ended September 30, 2016
 
Revenue Recognized From
 
Total
 
Upfront and Milestone Payments
 
Research and Development Services
 
ZIOPHARM Oncology, Inc.
$
6,687

 
$
17,693

 
$
24,380

Oragenics, Inc.
786

 
1,083

 
1,869

Fibrocell Science, Inc.
1,814

 
2,604

 
4,418

Genopaver, LLC
205

 
4,703

 
4,908

S & I Ophthalmic, LLC
—

 
6,326

 
6,326

OvaXon, LLC
—

 
2,211

 
2,211

Intrexon Energy Partners, LLC
1,875

 
11,180

 
13,055

Persea Bio, LLC
375

 
613

 
988

Ares Trading S.A.
4,791

 
2,148

 
6,939

Intrexon Energy Partners II, LLC
1,500

 
816

 
2,316

Intrexon T1D Partners, LLC
554

 
543

 
1,097

Harvest start-up entities (1)
776

 
1,890

 
2,666

Other
4,684

 
6,287

 
10,971

Total
$
24,047

 
$
58,097

 
$
82,144

(1)
For the nine months ended September 30, 2016, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; and AD Skincare, Inc.
Summary of Deferred Revenue
Deferred revenue consists of the following:
 
September 30,
2017
 
December 31,
2016
Upfront and milestone payments
$
269,649

 
$
297,867

Prepaid research and development services
1,718

 
6,015

Prepaid product and service revenues
4,869

 
5,554

Other
51

 
706

Total
$
276,287

 
$
310,142

Current portion of deferred revenue
$
48,289

 
$
53,364

Long-term portion of deferred revenue
227,998

 
256,778

Total
$
276,287

 
$
310,142
Summary of Deferred Revenue by Collaborator
The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant collaboration and licensing agreement.
 
September 30,
2017
 
December 31,
2016
ZIOPHARM Oncology, Inc.
$
124,282

 
$
138,809

Oragenics, Inc.
6,980

 
7,766

Fibrocell Science, Inc.
17,212

 
19,026

Genopaver, LLC
1,772

 
1,977

Intrexon Energy Partners, LLC
16,250

 
18,125

Persea Bio, LLC
3,625

 
4,000

Ares Trading S.A.
42,387

 
47,178

Intrexon Energy Partners II, LLC
14,333

 
15,833

Intrexon T1D Partners, LLC
8,628

 
8,653

Harvest start-up entities (1)
18,953

 
20,208

Other
15,227

 
16,292

Total
$
269,649

 
$
297,867

(1)
As of September 30, 2017 and December 31, 2016, the balance of deferred revenue for collaborations with Harvest start-up entities includes Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.